Posted by Michael Wonder on 06 Oct 2020
Next-generation wet AMD therapy Beovu, now available in Canada, receives positive recommendation from CADTH Drug Expert Committee
5 October 2020 - Positive recommendation by CADTH speaks to evidence and clinical benefit of Beovu.
Novartis Pharmaceuticals Canada is pleased to announce that Beovu (brolucizumab injection) is now available in Canada for the treatment of neovascular (wet) age-related macular degeneration (AMD). The next-generation anti-VEGF therapy for wet AMD, offers the option for eligible patients to start on three-month dosing intervals after the loading phase.
Beovu has been reviewed by the CADTH Canadian Drug Expert Committee and has received a positive recommendation for reimbursement by participating public health plans.
